一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Biomedicines >>article
Biomedicines

Biomedicines

IF: 3.9
Download PDF

Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in BRCA1/2-Proficient Cancer Cells

Published:14 April 2025 DOI: 10.3390/biomedicines13040958 PMID: 40299557
Danyang Zhou,?Wei Liu,?Yanyan Zhang,?Chong Li

Abstract

Background/Objectives: PARP inhibitors (PARPi) are pivotal to treating homologous recombination repair-deficient (HRD) cancers, particularly BRCA1/2-mutated ovarian and breast cancers. However, most ovarian and breast cancers harbor wild-type (WT) BRCA1/2, limiting PARPi eligibility. This study aims to identify an approved drug that could induce a BRCAness phenotype, thereby sensitizing WT BRCA cancers to PARPi. Methods: Ovarian and breast cancer cell lines with WT BRCA1/2 were treated with ivosidenib. HR repair efficiency was assessed via RAD51 foci formation and reporter assays. Synthetic lethality with PARPi was evaluated using viability and colony formation assays. Mechanistic studies included RNA-binding protein pulldown, co-immunoprecipitation, and functional analyses of DNA repair pathways. YTHDC2's role in HR was investigated through siRNA knockdown and rescue experiments. Results: Ivosidenib significantly reduced HR repair efficiency and sensitized cells to PARPi, inducing synthetic lethality. Mechanistically, ivosidenib directly bound YTHDC2, an m6A reader critical for HR. This interaction disrupted YTHDC2's ability to promote DNA double-strand break repair via HR, evidenced by impaired recruitment of repair proteins (e.g., BRCA1, RAD51) and accumulation of DNA damage (γH2AX foci). YTHDC2 knockdown phenocopied ivosidenib effects, while overexpression rescued HR defects. Conclusions: Ivosidenib induces BRCAness in WT BRCA ovarian and breast cancers by targeting YTHDC2, thereby suppressing HR repair and enhancing PARPi sensitivity. This uncovers a novel, metabolism-independent mechanism of ivosidenib, repositioning it as a therapeutic agent for HRD tumors. These findings propose a strategy to expand PARPi eligibility to WT BRCA cancers, addressing a critical unmet need in oncology.

Similar articles

IF:0.8

Andrographolide Induces Apoptosis in Gastric Cancer Cells through Reactivation of p53 and Inhibition of Mdm-2

Doklady Biochemistry and Biophysics Hongbo Gao, Hongyang Li,etc Published: 25 October 2021
IF:5.4

Modulation of Estrogen Receptor Alpha (ERα) and Tumor Suppressor Gene BRCA1 in Breast Cancer Cells by Bazedoxifene Acetate (BZA)

ACS Applied Energy Materials Monica Szmyd, Aisha Zanib,etc Published: 7 February 2024
IF:6.9

5-aza-2′-deoxycytidine induces telomere dysfunction in breast cancer cells

Biomedicine & Pharmacotherapy Sarah Al-dulaimi , Sheila Matta ,etc Published: 26 July 2024
乐东| 秀山| 武夷山市| 七台河市| 宜良县| 台山市| 阿瓦提县| 郓城县| 德阳市| 灵丘县| 翁牛特旗| 格尔木市| 且末县| 双江| 库伦旗| 宝鸡市| 宁乡县| 绥棱县| 东乡| 巴东县| 繁昌县| 楚雄市| 岳阳县| 石景山区| 应城市| 承德县| 三明市| 新晃| 浑源县| 武平县| 霍林郭勒市| 横山县| 开远市| 长宁区| 界首市| 三亚市| 高要市| 甘泉县| 张家川| 华坪县| 宜君县|